Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
Public ClinicalTrials.gov record NCT03939533. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Clinical Phase 3 Study to Monitor the Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin (CUTAQUIG®) Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
Study identification
- NCT ID
- NCT03939533
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Octapharma
- Industry
- Enrollment
- 64 participants
Conditions and interventions
Conditions
Interventions
- CUTAQUIG Drug
Drug
Eligibility (public fields only)
- Age range
- 2 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 16, 2019
- Primary completion
- Jan 2, 2022
- Completion
- Jan 2, 2022
- Last update posted
- Nov 6, 2023
2019 – 2022
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Octapharma Research Site | Scottsdale | Arizona | 85251 | — |
| Octapharma Research Site | Irvine | California | 92697 | — |
| Octapharma Research Site | Santa Barbara | California | 93105 | — |
| Octapharma Research Site | Centennial | Colorado | 80112 | — |
| Octapharma Research Site | North Palm Beach | Florida | 33408 | — |
| Octapharma Research Site | St. Petersburg | Florida | 33701 | — |
| Octapharma Research Site | Albany | Georgia | 31707 | — |
| Octapharma Research Site | Louisville | Kentucky | 40215 | — |
| Octapharma Research Site | Chevy Chase | Maryland | 20815 | — |
| Octapharma Research Site | St Louis | Missouri | 63141 | — |
| Octapharma Research Site | Papillion | Nebraska | 68046 | — |
| Octapharma Research Site | Asheville | North Carolina | 28801 | — |
| Octapharma Research Site | Cincinnati | Ohio | 45231 | — |
| Octapharma Research Site | Mayfield | Ohio | 44124 | — |
| Octapharma Research Site | Toledo | Ohio | 43617 | — |
| Octapharma Research Site | Pittsburgh | Pennsylvania | 15241 | — |
| Octapharma Research Site | Dallas | Texas | 75225 | — |
| Octapharma Research Site | Bellingham | Washington | 98225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03939533, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 6, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03939533 live on ClinicalTrials.gov.